Journal of Cancer Research and Therapeutics Close
 

Figure 3: Liver IHC-caspase-3: (a) Control untreated rats: no/very weak cytoplasmic staining in individual hepatocyte. (b) BME-treated rats: moderate cytoplasmic and membranous hepatocellular staining. (c) Cisplatin-treated rats: moderate cytoplasmic and membranous staining of many hepatocytes. (d) Cisplatin and BME co-treated rats: intense cytoplasmic and membranous staining of many hepatocytes (×400)

Figure 3: Liver IHC-caspase-3: (a) Control untreated rats: no/very weak cytoplasmic staining in individual hepatocyte. (b) BME-treated rats: moderate cytoplasmic and membranous hepatocellular staining. (c) Cisplatin-treated rats: moderate cytoplasmic and membranous staining of many hepatocytes. (d) Cisplatin and BME co-treated rats: intense cytoplasmic and membranous staining of many hepatocytes (×400)